JP2019519570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519570A5 JP2019519570A5 JP2018568195A JP2018568195A JP2019519570A5 JP 2019519570 A5 JP2019519570 A5 JP 2019519570A5 JP 2018568195 A JP2018568195 A JP 2018568195A JP 2018568195 A JP2018568195 A JP 2018568195A JP 2019519570 A5 JP2019519570 A5 JP 2019519570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- concentration
- brincidofovir
- aqueous
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 74
- WXJFKKQWPMNTIM-VWLOTQADSA-N [(2s)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O WXJFKKQWPMNTIM-VWLOTQADSA-N 0.000 claims description 39
- 229950005107 brincidofovir Drugs 0.000 claims description 39
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 26
- 229930195725 Mannitol Natural products 0.000 claims description 26
- 239000000594 mannitol Substances 0.000 claims description 26
- 235000010355 mannitol Nutrition 0.000 claims description 26
- 239000004067 bulking agent Substances 0.000 claims description 25
- 239000000872 buffer Substances 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008121 dextrose Substances 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 14
- 230000009385 viral infection Effects 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- 208000036142 Viral infection Diseases 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 235000009697 arginine Nutrition 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 206010018910 Haemolysis Diseases 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000008588 hemolysis Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021075612A JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
| JP2023005643A JP7407984B2 (ja) | 2016-06-28 | 2023-01-18 | ブリンシドフォビルの製剤 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355844P | 2016-06-28 | 2016-06-28 | |
| US62/355,844 | 2016-06-28 | ||
| US201662394665P | 2016-09-14 | 2016-09-14 | |
| US62/394,665 | 2016-09-14 | ||
| US201762446213P | 2017-01-13 | 2017-01-13 | |
| US62/446,213 | 2017-01-13 | ||
| US201762465053P | 2017-02-28 | 2017-02-28 | |
| US62/465,053 | 2017-02-28 | ||
| US201762507397P | 2017-05-17 | 2017-05-17 | |
| US62/507,397 | 2017-05-17 | ||
| US201762512825P | 2017-05-31 | 2017-05-31 | |
| US62/512,825 | 2017-05-31 | ||
| PCT/US2017/039804 WO2018005676A1 (en) | 2016-06-28 | 2017-06-28 | Formulations of brincidofovir |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021075612A Division JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519570A JP2019519570A (ja) | 2019-07-11 |
| JP2019519570A5 true JP2019519570A5 (enExample) | 2020-02-20 |
| JP6878473B2 JP6878473B2 (ja) | 2021-05-26 |
Family
ID=59313330
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568195A Active JP6878473B2 (ja) | 2016-06-28 | 2017-06-28 | ブリンシドフォビルの製剤 |
| JP2021075612A Active JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
| JP2023005643A Active JP7407984B2 (ja) | 2016-06-28 | 2023-01-18 | ブリンシドフォビルの製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021075612A Active JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
| JP2023005643A Active JP7407984B2 (ja) | 2016-06-28 | 2023-01-18 | ブリンシドフォビルの製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20170368082A1 (enExample) |
| EP (2) | EP4295853A3 (enExample) |
| JP (3) | JP6878473B2 (enExample) |
| CN (4) | CN118416082A (enExample) |
| AU (2) | AU2017290703B2 (enExample) |
| CA (1) | CA3024886A1 (enExample) |
| DK (1) | DK3474822T3 (enExample) |
| ES (1) | ES3037596T3 (enExample) |
| FI (1) | FI3474822T3 (enExample) |
| PL (1) | PL3474822T3 (enExample) |
| PT (1) | PT3474822T (enExample) |
| WO (1) | WO2018005676A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015073148A1 (en) | 2013-11-15 | 2015-05-21 | Chimerix Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters |
| CN118416082A (zh) * | 2016-06-28 | 2024-08-02 | 应急生物防御行动兰辛有限责任公司 | 布林西多福韦的制剂 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CN114073772A (zh) * | 2020-08-18 | 2022-02-22 | 上海市公共卫生临床中心 | 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途 |
| CN114558022B (zh) * | 2022-02-16 | 2023-11-17 | 华中农业大学 | 布林西多福韦在制备抗伪狂犬病毒药物中的应用 |
| CN114732821A (zh) * | 2022-04-24 | 2022-07-12 | 华中农业大学 | 西多福韦的前药在制备防治非洲猪瘟药物中的应用 |
| JP7417339B1 (ja) * | 2023-08-07 | 2024-01-18 | シンバイオ製薬株式会社 | アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療 |
| WO2025072782A1 (en) * | 2023-09-29 | 2025-04-03 | Symbio Pharmaceuticals Limited | Brincidofovir for treatment of multiple sclerosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02005490A (es) | 1999-12-03 | 2004-09-10 | Univ California San Diego | Compuestos de fosfonato. |
| JP4136340B2 (ja) * | 2000-08-18 | 2008-08-20 | 武田薬品工業株式会社 | 注射剤 |
| JP2008538354A (ja) | 2005-04-08 | 2008-10-23 | キメリクス，インコーポレイテッド | ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法 |
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| JP2010525063A (ja) * | 2007-04-27 | 2010-07-22 | キメリクス，インコーポレイテッド | ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 |
| JP2011116658A (ja) | 2008-03-13 | 2011-06-16 | Chemo-Sero-Therapeutic Research Inst | 豚萎縮性鼻炎用薬剤の製造方法 |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| AU2010279678B2 (en) | 2009-08-03 | 2015-09-10 | Emergent Biodefense Operations Lansing Llc | Composition and methods of treating viral infections and viral induced tumors |
| CA2779473C (en) | 2009-10-30 | 2016-08-16 | Chimerix, Inc. | Methods of treating viral associated diseases |
| ES2547698T3 (es) | 2009-12-03 | 2015-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo |
| US20110263536A1 (en) | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
| CN103209985B (zh) | 2010-08-31 | 2016-08-24 | 奇默里克斯公司 | 膦酸酯衍生物及其合成方法 |
| EP2770834A4 (en) * | 2011-10-26 | 2015-11-25 | Chimerix Inc | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| WO2013163509A1 (en) | 2012-04-27 | 2013-10-31 | Chimerix, Inc. | A method of mitigating virus associated end-organ damage |
| UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| WO2015073148A1 (en) * | 2013-11-15 | 2015-05-21 | Chimerix Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters |
| CN118416082A (zh) * | 2016-06-28 | 2024-08-02 | 应急生物防御行动兰辛有限责任公司 | 布林西多福韦的制剂 |
-
2017
- 2017-06-28 CN CN202410393564.XA patent/CN118416082A/zh active Pending
- 2017-06-28 FI FIEP17737695.1T patent/FI3474822T3/fi active
- 2017-06-28 EP EP23195544.4A patent/EP4295853A3/en active Pending
- 2017-06-28 PL PL17737695.1T patent/PL3474822T3/pl unknown
- 2017-06-28 US US15/636,393 patent/US20170368082A1/en not_active Abandoned
- 2017-06-28 PT PT177376951T patent/PT3474822T/pt unknown
- 2017-06-28 ES ES17737695T patent/ES3037596T3/es active Active
- 2017-06-28 CN CN201780040478.9A patent/CN109475497A/zh active Pending
- 2017-06-28 JP JP2018568195A patent/JP6878473B2/ja active Active
- 2017-06-28 WO PCT/US2017/039804 patent/WO2018005676A1/en not_active Ceased
- 2017-06-28 DK DK17737695.1T patent/DK3474822T3/da active
- 2017-06-28 EP EP17737695.1A patent/EP3474822B1/en active Active
- 2017-06-28 CN CN202210134248.1A patent/CN114569547A/zh active Pending
- 2017-06-28 CN CN202411127002.7A patent/CN119139329A/zh active Pending
- 2017-06-28 AU AU2017290703A patent/AU2017290703B2/en active Active
- 2017-06-28 CA CA3024886A patent/CA3024886A1/en active Pending
-
2019
- 2019-12-20 US US16/722,699 patent/US20200138835A1/en not_active Abandoned
-
2021
- 2021-04-28 JP JP2021075612A patent/JP7221485B2/ja active Active
-
2022
- 2022-07-25 US US17/872,921 patent/US12485131B2/en active Active
-
2023
- 2023-01-18 JP JP2023005643A patent/JP7407984B2/ja active Active
- 2023-06-28 AU AU2023204117A patent/AU2023204117B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519570A5 (enExample) | ||
| Chaturvedi et al. | A review on mucoadhesive polymer used in nasal drug delivery system | |
| JP2023033538A5 (enExample) | ||
| ES2543108T3 (es) | Preparación sólida fácilmente administrable | |
| JP2018533547A (ja) | ワクチン組成物 | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| FI3474822T3 (fi) | Brinsidofoviirin formulaatioita | |
| KR20130083376A (ko) | 비강내 전달을 위한 방법 및 조성물 | |
| CA2945201C (en) | Vaccine compositions | |
| JP2002363097A (ja) | 安定化された凍結乾燥型医薬組成物 | |
| JP6488003B2 (ja) | 安定なモンテルカスト溶液 | |
| JP2015515968A5 (enExample) | ||
| JP2015512441A5 (enExample) | ||
| RU2488384C2 (ru) | Композиции для лечения неопластических заболеваний | |
| CN116605906B (zh) | 硫化铋银纳米材料的合成方法及其抗病毒应用 | |
| CN101773478B (zh) | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 | |
| JP6346945B2 (ja) | 安定な静脈内製剤 | |
| WO2022083729A1 (en) | Compositions of anti-viral peptides and/or compounds and methods of use thereof | |
| KR102631084B1 (ko) | 면역 반응 증강용 복합체 | |
| JP2017533252A (ja) | Ｃ型肝炎のための長時間作用型医薬組成物 | |
| JPWO2017090766A1 (ja) | 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法 | |
| RU2018123711A (ru) | Композиции для внутривенного введения | |
| CN114206319B (zh) | 用于治疗hbv的药物组合物 | |
| WO2025120580A1 (en) | Compositions and methods for initiating a mucosal immune response | |
| JP2019507195A5 (enExample) |